Dermatology

413.6K Papers

Follow See full results

Article Dermatology

Cannabinoids in hyperhidrosis

Till Kaemmerer, Benjamin Maximilian Clanner-Engelshofen, Tony Lesmeister, Lars Einar French, Markus Reinholz

Summary: Hyperhidrosis significantly impacts patient's quality of life, especially in cases of generalized hyperhidrosis. In this open trial, a refractory case of generalized hyperhidrosis was treated with cannabinoids, resulting in a remarkable reduction in sweat volume and improvement in the patient's quality of life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review

Nicole Natarelli, Amanda Krenitsky, Kerry Hennessy, Sarah Moore, James Grichnik

Summary: This systematic review assessed the efficacy and safety of topical treatments for seborrheic keratoses (SKs). Topical treatments such as hydrogen peroxide were found to be effective in clearing SKs, with mild and transient side effects. However, there is still a need for topical treatments that reliably surpass current first-line therapies.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

Rachel C. C. Ruda, Katherine A. A. Kelly, Steven R. R. Feldman

Summary: Tumor necrosis factor (TNF) inhibitors have been effective for psoriasis treatment, but their high cost limits their accessibility. Biosimilars offer a lower-cost alternative and have shown comparable safety and efficacy to the reference products in real-world studies. While these studies have limitations, they suggest that patients can safely switch to biosimilar therapies for psoriasis treatment.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Diane M. Thiboutot, Noah Craft, Robert Rissmann, Ewa Gatlik, Malika Souquieres, Julie Jones, Christian Loesche

Summary: Blocking IL-17A with CJM112 did not show significant efficacy in reducing inflammatory lesions in patients with moderate to severe acne.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan

Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Summary: Switching from baricitinib 4 mg to upadacitinib 30 mg effectively improved rash and pruritus in Japanese patients with moderate-to-severe AD. Total EASI, EASI at each anatomical site, EASI of each clinical sign, and PP-NRS were significantly reduced at weeks 4 or 12 after switching. The achievement rates of more than 75% or 90% reduction of EASI from baseline significantly improved after switching.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review

Qingqing Li

Summary: Langerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes. Vemurafenib, a BRAF inhibitor, has shown good response in the treatment of LCH.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis Puig

Summary: The purpose of this literature review is to examine the impact of IMID treatments on the immunogenicity of SARS-CoV-2 vaccination. The results show that patients receiving secukinumab treatment for IMIDs have an adequate immune response to SARS-CoV-2 vaccines, and there is no evidence of impaired immune function.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe

Summary: The study aimed to estimate the prevalence of SARS-CoV-2 infection in psoriasis patients, compare infection rates among different treatment groups, and describe severe COVID-19 cases. The findings suggest that the risk of SARS-CoV-2 infection is not increased for psoriasis patients using biologics or non-biologic systemic therapy compared to other treatments.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

The landscape of vitiligo in Latin America: a call to action

Angela Londono-Garcia, Andrea Arango Salgado, Maria de la Luz Orozco-Covarrubias, Angela Marie Jansen, Mariana Rico-Restrepo, Maria Cecilia Riviti, Margarita Maria Velasquez-Lopera, Carla Castro

Summary: This paper examines the journey of a vitiligo patient in Latin America and assesses the disease landscape. Lack of disease awareness and research, social ostracization, and limited therapeutic options hinder patients in their quest for diagnosis and treatment. Timely access to diagnosis and treatment is crucial for improving outcomes, and collaboration is needed to eliminate these challenges.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis

Jashin J. Wu, Ching An Wang, Greeta Jobson, David Davidson, Samaneh Kalirai, Julia Zhu, Manasi Suryavanshi, Mayank Mittal, Vardhaman Patel, Lauren Seigel

Summary: The study compared treatment patterns and healthcare costs for psoriasis patients starting apremilast, tumor necrosis factor inhibitors, or interleukin inhibitors. Results showed higher switch rates for tumor necrosis factor inhibitors, while apremilast had lower costs despite lower effectiveness reported in previous studies. Patient preference for oral treatment may explain this. Additional oral options may be desirable for this population.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data

Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi, John Koo

Summary: Patients with psoriasis have a higher risk of depression and suicidality, but it is unclear whether biologic or oral agents are more effective in treating depressive symptoms. This study analyzed postmarketing data to estimate the odds of depression in psoriasis patients on different systemic therapies. The results suggest that biologics may be more effective at reducing incident depression compared to oral agents, but further controlled trials are needed for confirmation.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Letter Dermatology

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

L. Mastorino, F. Gelato, P. Quaglino, M. Ortoncelli, S. Ribero

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

An updated systematic review and meta-analysis of efficacy and safety of Chinese herbal medicine for treating atopic dermatitis

Jinjing Jia, Sherman X. Gu, Xiumei Mo, Junfeng Liu, Dacan Chen

Summary: This systematic review evaluated the effectiveness of Chinese herbal medicine in treating atopic dermatitis. The results showed that Chinese herbal medicine could improve the overall recovery rate and decrease the recurrence rate. However, more studies are needed to validate its potential in terms of disease/symptom severity and quality of life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

An 8-year follow-up of IgG4-related skin disease presented with generalized ALHE-like eruptions: successful treatment of glucocorticoid and cyclophosphamide

Guanyu Wang, Ping Tu, Jing Su, Wenting Wu, Chunlei Zhang, Wenhui Wang, Weiwei Li

Summary: Immunoglobulin G4-related skin disease is a rare immunologic disorder affecting multiple organs. This case study reports a rare case of IgG4-related skin disease treated successfully with oral glucocorticoid and cyclophosphamide, resulting in complete remission and no relapse or disease progression observed during an 8-year follow-up.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Review Dermatology

Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

Yuanyuan Qiu, Yang Zhu, Yun Liu, Qiliang Liu

Summary: This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis. Six randomized controlled trials involving 1252 participants were analyzed, and the results showed that bimekizumab was more effective than placebo in improving psoriasis symptoms, with no significant adverse events. Therefore, bimekizumab holds great promise for the treatment of psoriasis.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Letter Dermatology

High-risk squamous cell carcinoma, a surgical challenge: the other face of the SARS-CoV-2 pandemic

Alvaro Prados-Carmona, Jose Maria Llamas-Molina, Pablo Velasco-Amador, Ricardo Ruiz-Villaverde, Jose Carlos Ruiz-Carrascosa

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study

Angela L. Bosma, Louise A. A. Gerbens, Hajar El Khattabi, Floris C. Loeff, Michael Duckworth, Richard T. Woolf, Theo Rispens, Catherine H. Smith, Phyllis I. Spuls

Summary: This study investigated the clinical relevance of dupilumab serum concentration in atopic dermatitis patients. The results showed that the concentration of dupilumab is not associated with treatment effectiveness, but disease activity does seem to influence its levels.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Photodynamic therapy combined with surgery versus Mohs micrographic surgery for the treatment of difficult-to-treat basal cell carcinoma: a retrospective clinical study

Nianzhou Yu, Lisha Wu, Juan Su, Mingliang Chen, Lixia Lu, Kai Huang, Yixin Li, Zixi Jiang, Siliang Liu, Lanyuan Peng, Yang Xie, Zeyu Chen, Wenhu Zhou, Miaojian Wan, Fang Fang, WenBo Bu, Shuang Zhao

Summary: This study compared the efficacy and safety of photodynamic therapy combined with surgery (S-PDT) and Mohs micrographic surgery (MMS) for the treatment of difficult-to-treat basal cell carcinoma (BCC). The results showed no statistical difference in recurrence rate between the two treatment methods, but S-PDT had a longer healing time and no significant difference in cosmetic outcome compared to MMS. In conclusion, S-PDT is a safe and effective alternative treatment to MMS for certain cases.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

A new method to treat onychopapilloma with pulsed dye laser irradiation: a 13-case series report

Xing Fan, Tong Li, Xi Zhang, Juan Yang, Jiangbo Cui, Wenjie Dou, Yue Yin, Qing Yang, Ping Xue, Bin Liu, Yang Li

Summary: This study reports a new method to treat onychopapilloma with pulsed dye laser (PDL). The overall effective rate of PDL treatment for onychopapilloma was 77%, with effective rates of 88%, 67%, and 50% for erythronychia, leukonychia, and melanonychia, respectively.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg, Jeff Crowley

Summary: This study aims to compare the real-world dose escalation of risankizumab with other FDA-approved biologic treatments for moderate-to-severe psoriasis in the United States. The results show that a significantly lower proportion of patients treated with risankizumab had dose escalations compared to those treated with other biologics.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.